الفهرس 
PRIMARY MYELOFIBROSISOnly 14 pages are availabe for public view
 |  | from | 150 |  |  |
| | | from | 150 | | |
Abstract
switching to ruxolitinib in non-Allo-SCT patients showed a trend towards lower mortality. For the remission phase, patients who underwent Allo-SCT had the shortest time in the “illness” state before achieving remission, death, or censorship, with an average time of 28 days, followed by ruxolitinib, with an average illness duration of 157 days. Patients who were treated with ruxolitinib had the longest time in the symptomatic free phase, with an average time of 573 days, followed by 495 days for patients who underwent Allo-SCT but the patient achieved disease remission. Patients who received hydroxyurea or HSFs only had the shortest Rmean durations of 132 and 115 days. Allo-SCT was found to be significantly associated with higher hemoglobin levels by more than 2 g/dl on averageand decrease of the splenic size throughout the study duration.
Conclusion: In the era of new novel therapies for PMF, HSCT remain the only curative option and should be considered for individuals with intermediate-2, high-risk disease. In the future should be discussed in young patients, regardless of their risk score, to leverage age, favorable performance status, and less exposure to prior therapies.